GlassScriptPhysician profile
Polly Kanganis
NPI 1477644698
$806.17
in general payments reported to CMS, 2019-2025
13 companies · $37.25 in 2025
The $37.25 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.73 · 2020: $102 · 2021: $54.38 · 2022: $168 · 2023: $311 · 2024: $95.20 · 2025: $37.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $442.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $370.88 | 2020-2024 | |
| Hologic Sales and Service, LLC | $92.56 | 2020-2025 | Thinprep 2000 Processor |
| Coopersurgical, INC. | $62.85 | 2022-2025 | Paragard T 380a |
| Exeltis, USA INC. | $59.89 | 2021-2022 | |
| Amgen INC. | $47.47 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $29.68 | 2023 | Zilretta, Iovera |
| Shield Therapeutics INC | $24.05 | 2023 | Accrufer |
| Pfizer INC. | $23.64 | 2022 | |
| Astellas Pharma US INC | $22.66 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $20.70 | 2023 | Myfembree |
| Evofem Biosciences, INC. | $20.45 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.10 | 2019 | |
| Avion Pharmaceuticals | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Polly Kanganis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.